When multiple myeloma relapses

RESPOND with KRd – Improvement in quality of life shown from cycle 3 onwards

KRd quality of life data

In the ASPIRE trial, health-related quality of life scores were higher in the KRd vs the Rd group.1 The minimal clinically important difference for between-group differences is 5.0 points, which was met at cycle 2 (5.6 points) and approached at cycle 18 (4.8 points).1

Adapted from Stewart et al.1

A KRd regimen results in greater QoL scores than an Rd regimen.1

*Descriptive P value (one-sided). The KRd group reported improved global health status based on the QLQ-C30 global health status/QoL scale vs Rd over 18 cycles of treatment (P<0.001). The minimal clinically important difference for between-group differences on the QLQ-C30 Global Health Status and Quality of Life scale is 5.0 points, which was met at cycle 12 (5.6 points) and approached at cycle 18 (4.8 points).1
The QLQ-C30 questionnaire includes five functional scales (physical, role, emotional, cognitive and social), three symptom scales (including fatigue, nausea and vomiting, pain and insomnia), a global health status/QoL scale, and six single items.

Please read the SmPC for full comprehensive safety information

References

  1. Stewart AK et al. N Engl J Med 2015;372:142–152.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis